Eli Lilly (NYSE:LLY)
Historical Stock Chart
2 Months : From Dec 2019 to Feb 2020
By Stephen Nakrosis
Eli Lilly and Co. (LLY) said Monday the U.S. Food and Drug Administration approved Trijardy to lower blood sugar in adults with type 2 diabetes.
Lilly said Trijardy XR, which is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly, combines three medicines--Jardiance, or empagliflozin, Tradjenta, or linagliptin, and metformin hydrochloride extended release--in one pill.
Trijardy is indicated for use along with diet and exercise to lower blood sugar.
Trijardy is a once-a-day medication, Lilly said, adding it will be available in four different dosages.
--Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires
January 27, 2020 18:16 ET (23:16 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.